An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating physician according to the World Health Organization (WHO)
Treatment with ruxolitinib for ≥18 weeks prior to study entry, and on a stable dose of ruxolitinib in the 8 weeks prior to study entry
Spleen ≥5 cm palpable below the LLCM or ≥450 cm3 by MRI or CT
Patients must have at least 2 symptoms with a score of at least 1 on the MFSAF v4.0
ECOG performance status of 0 to 2
You may not be if
Patients who are positive for TP53 mutations
Documented disease progression or clinical deterioration any time while on ruxolitinib treatment
Patients who have had a documented spleen response to ruxolitinib.
Prior splenectomy
Prior MDM2 inhibitor therapy or p53-directed therapy
Clareo Health | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
